CXCR2, or C-X-C chemokine receptor type 2, is a G protein-coupled receptor that binds to various chemokines, including CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 (also known as IL-8). It plays a significant role in the recruitment and activation of neutrophils during inflammation and is implicated in the pathogenesis of various diseases, including cancer. In the context of oncology, CXCR2 expression has been associated with tumor growth, angiogenesis, metastasis, and immune evasion. The receptor's interaction with its ligands can activate multiple signaling pathways, leading to the promotion of tumor-associated inflammation and immune suppression. Targeting CXCR2 and its signaling axis is being explored as a therapeutic strategy in cancer treatment, with potential applications in sensitizing tumors to immunotherapies and inhibiting cancer progression. Structural insights into CXCR2, such as those gained from cryo-electron microscopy and X-ray crystallography, are aiding in the development of small molecule inhibitors and other therapeutic agents.